Last reviewed · How we verify
AMSCs
At a glance
| Generic name | AMSCs |
|---|---|
| Sponsor | Sanjeet S. Grewal |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of REcycled CartiLage Auto/Allo IMplantation to Treat and Repair Focal Hip Cartilage Defects (PHASE1)
- Autologous Culture Expanded Adipose Derived MSCs for Treatment of Painful Hip OA (PHASE1)
- Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy (PHASE1)
- Allogenic Adipose-derived Mesenchymal Stem Cells(AMSCs) for Epilepsy During Deep Brain Stimulation(DBS) Surgery (EARLY_PHASE1)
- REcycled CartiLage Auto/Allo IMplantation (PHASE1)
- Autologous Culture Expanded Mesenchymal Stromal Cells for Knee Osteoarthritis (PHASE1)
- Feasibility and Safety of Allogeneic Adipose Mesenchymal Stem Cells (aMSCs) Delivery Into Kidney Allografts Procured From Deceased Donors With High Kidney Donor Profile Index (KDPI) (PHASE1)
- Adipose Derived SVF for Aero-digestive & Enterocutaneous Fistulae (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AMSCs CI brief — competitive landscape report
- AMSCs updates RSS · CI watch RSS
- Sanjeet S. Grewal portfolio CI